Search research articles
Contact Us
Filters
Showing results (1-10 of 45) with videos related to
Page
of 5
Sort By:
Hamostaseologie
|
May 5, 2007
[Long-term prophylaxis in congenital haemophilia with inhibitors - experiences with rFVIIa]
G Auerswald
Thrombosis Research
|
April 1, 2006
Prophylaxis in rare coagulation disorders -- factor X deficiency
G Auerswald
MMW Fortschritte Der Medizin
|
September 24, 2009
[Diagnosis of coagulation disorders: first steps to be done]
G Auerswald
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 17, 2008
Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience
G Auerswald, W Kreuz
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 29, 2011
Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience
G Auerswald, C Bidlingmaier, K Kurnik
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
January 8, 2009
Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention
M E Mancuso, L Graca, G Auerswald, et al.
Fortschritte Der Medizin
|
December 4, 1975
[Modification of infectious-allergic processes by oral administration of antigens]
H Stickl, G Auerswald, U Boden, et al.
Thrombosis and Haemostasis
|
November 1, 1994
Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors
S Ehrenforth, W Kreuz, M Funk, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 27, 2018
Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica
A Seuser, M Navarrete-Duran, G Auerswald, et al.
Hamostaseologie
|
November 3, 2010
[Inhibitor development after early high exposure and cerebral haemorrhage. Costs and factor demand for a successful immunotolerance induction therapy]
K Haubold, C Moorthi, A Bade, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 45) with videos related to
Sort By:
Page
of 5
Hamostaseologie
|
May 5, 2007
[Long-term prophylaxis in congenital haemophilia with inhibitors - experiences with rFVIIa]
G Auerswald
Thrombosis Research
|
April 1, 2006
Prophylaxis in rare coagulation disorders -- factor X deficiency
G Auerswald
MMW Fortschritte Der Medizin
|
September 24, 2009
[Diagnosis of coagulation disorders: first steps to be done]
G Auerswald
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 17, 2008
Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience
G Auerswald, W Kreuz
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 29, 2011
Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience
G Auerswald, C Bidlingmaier, K Kurnik
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
January 8, 2009
Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention
M E Mancuso, L Graca, G Auerswald, et al.
Fortschritte Der Medizin
|
December 4, 1975
[Modification of infectious-allergic processes by oral administration of antigens]
H Stickl, G Auerswald, U Boden, et al.
Thrombosis and Haemostasis
|
November 1, 1994
Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors
S Ehrenforth, W Kreuz, M Funk, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 27, 2018
Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica
A Seuser, M Navarrete-Duran, G Auerswald, et al.
Hamostaseologie
|
November 3, 2010
[Inhibitor development after early high exposure and cerebral haemorrhage. Costs and factor demand for a successful immunotolerance induction therapy]
K Haubold, C Moorthi, A Bade, et al.
Page
of 5